Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for AF Recurrence in Structural Heart Disease
NCT06556732Phase 1Recruiting
- Sponsor
- Assiut University
- Start
- Aug 2024
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eplerenone in Atrial fibrillation (AFib) (2 arms), sponsored by Assiut University. Primary endpoint: Atrial Fibrillation Recurrence at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
eplerenone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06556732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556732.